Girish N Nadkarni1, Veena Rao2, Faramarz Ismail-Beigi3, Vivian A Fonseca4, Sudhir V Shah5, Michael S Simonson3, Lloyd Cantley2, Prasad Devarajan6, Chirag R Parikh2, Steven G Coca7. 1. Department of Medicine, Division of Nephrology, Icahn School of Medicine at Mount Sinai, New York, New York; 2. Department of Medicine, Division of Nephrology, Yale University School of Medicine, New Haven, Connecticut; 3. Department of Medicine, Division of Clinical and Molecular Endocrinology, Case Western Reserve University, Cleveland, Ohio; 4. Department of Medicine, Division of Endocrinology, Tulane University, New Orleans, Louisiana; 5. Department of Medicine, Division of Nephrology, University of Arkansas Medical Sciences, Little Rock, Arkansas; and. 6. Department of Pediatrics, Division of Nephrology, University of Cincinnati, Cincinnati, Ohio. 7. Department of Medicine, Division of Nephrology, Icahn School of Medicine at Mount Sinai, New York, New York; steven.coca@mssm.edu.
Abstract
BACKGROUND AND OBJECTIVES: Current measures for predicting renal functional decline in patients with type 2 diabetes with preserved renal function are unsatisfactory, and multiple markers assessing various biologic axes may improve prediction. We examined the association of four biomarker-to-creatinine ratio levels (monocyte chemotactic protein-1, IL-18, kidney injury molecule-1, and YKL-40) with renal outcome. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We used a nested case-control design in the Action to Control Cardiovascular Disease Trial by matching 190 participants with ≥40% sustained eGFR decline over the 5-year follow-up period to 190 participants with ≤10% eGFR decline in a 1:1 fashion on key characteristics (age within 5 years, sex, race, baseline albumin-to-creatinine ratio within 20 μg/mg, and baseline eGFR within 10 ml/min per 1.73 m(2)), with ≤10% decline. We used a Mesoscale Multiplex Platform and measured biomarkers in baseline and 24-month specimens, and we examined biomarker associations with outcome using conditional logistic regression. RESULTS: Baseline and 24-month levels of monocyte chemotactic protein-1-to-creatinine ratio levels were higher for cases versus controls. The highest quartile of baseline monocyte chemotactic protein-1-to-creatinine ratio had fivefold greater odds, and each log increment had 2.27-fold higher odds for outcome (odds ratio, 5.27; 95% confidence interval, 2.19 to 12.71 and odds ratio, 2.27; 95% confidence interval, 1.44 to 3.58, respectively). IL-18-to-creatinine ratio, kidney injury molecule-1-to-creatinine ratio, and YKL-40-to-creatinine ratio were not consistently associated with outcome. C statistic for traditional predictors of eGFR decline was 0.70, which improved significantly to 0.74 with monocyte chemotactic protein-1-to-creatinine ratio. CONCLUSIONS: Urinary monocyte chemotactic protein-1-to-creatinine ratio concentrations were strongly associated with sustained renal decline in patients with type 2 diabetes with preserved renal function.
BACKGROUND AND OBJECTIVES: Current measures for predicting renal functional decline in patients with type 2 diabetes with preserved renal function are unsatisfactory, and multiple markers assessing various biologic axes may improve prediction. We examined the association of four biomarker-to-creatinine ratio levels (monocyte chemotactic protein-1, IL-18, kidney injury molecule-1, and YKL-40) with renal outcome. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We used a nested case-control design in the Action to Control Cardiovascular Disease Trial by matching 190 participants with ≥40% sustained eGFR decline over the 5-year follow-up period to 190 participants with ≤10% eGFR decline in a 1:1 fashion on key characteristics (age within 5 years, sex, race, baseline albumin-to-creatinine ratio within 20 μg/mg, and baseline eGFR within 10 ml/min per 1.73 m(2)), with ≤10% decline. We used a Mesoscale Multiplex Platform and measured biomarkers in baseline and 24-month specimens, and we examined biomarker associations with outcome using conditional logistic regression. RESULTS: Baseline and 24-month levels of monocyte chemotactic protein-1-to-creatinine ratio levels were higher for cases versus controls. The highest quartile of baseline monocyte chemotactic protein-1-to-creatinine ratio had fivefold greater odds, and each log increment had 2.27-fold higher odds for outcome (odds ratio, 5.27; 95% confidence interval, 2.19 to 12.71 and odds ratio, 2.27; 95% confidence interval, 1.44 to 3.58, respectively). IL-18-to-creatinine ratio, kidney injury molecule-1-to-creatinine ratio, and YKL-40-to-creatinine ratio were not consistently associated with outcome. C statistic for traditional predictors of eGFR decline was 0.70, which improved significantly to 0.74 with monocyte chemotactic protein-1-to-creatinine ratio. CONCLUSIONS: Urinary monocyte chemotactic protein-1-to-creatinine ratio concentrations were strongly associated with sustained renal decline in patients with type 2 diabetes with preserved renal function.
Authors: Edward D Siew; T Alp Ikizler; Tebeb Gebretsadik; Ayumi Shintani; Nancy Wickersham; Frederick Bossert; Josh F Peterson; Chirag R Parikh; Addison K May; Lorraine B Ware Journal: Clin J Am Soc Nephrol Date: 2010-06-17 Impact factor: 8.237
Authors: Maryam Afkarian; Michael C Sachs; Bryan Kestenbaum; Irl B Hirsch; Katherine R Tuttle; Jonathan Himmelfarb; Ian H de Boer Journal: J Am Soc Nephrol Date: 2013-01-29 Impact factor: 10.121
Authors: Chirag R Parikh; Alkesh Jani; Vyacheslav Y Melnikov; Sarah Faubel; Charles L Edelstein Journal: Am J Kidney Dis Date: 2004-03 Impact factor: 8.860
Authors: Goodarz Danaei; Mariel M Finucane; Yuan Lu; Gitanjali M Singh; Melanie J Cowan; Christopher J Paciorek; John K Lin; Farshad Farzadfar; Young-Ho Khang; Gretchen A Stevens; Mayuree Rao; Mohammed K Ali; Leanne M Riley; Carolyn A Robinson; Majid Ezzati Journal: Lancet Date: 2011-06-24 Impact factor: 79.321
Authors: Michelle J Pena; Andreas Heinzel; Georg Heinze; Alaa Alkhalaf; Stephan J L Bakker; Tri Q Nguyen; Roel Goldschmeding; Henk J G Bilo; Paul Perco; Bernd Mayer; Dick de Zeeuw; Hiddo J Lambers Heerspink Journal: PLoS One Date: 2015-05-14 Impact factor: 3.240
Authors: David R W Jayne; Annette N Bruchfeld; Lorraine Harper; Matthias Schaier; Michael C Venning; Patrick Hamilton; Volker Burst; Franziska Grundmann; Michel Jadoul; István Szombati; Vladimír Tesař; Mårten Segelmark; Antonia Potarca; Thomas J Schall; Pirow Bekker Journal: J Am Soc Nephrol Date: 2017-04-11 Impact factor: 10.121
Authors: Simon B Ascher; Rebecca Scherzer; Michelle M Estrella; Michael G Shlipak; Derek K Ng; Frank J Palella; Mallory D Witt; Ken Ho; Michael R Bennett; Chirag R Parikh; Joachim H Ix; Vasantha Jotwani Journal: Am J Nephrol Date: 2019-09-25 Impact factor: 3.754
Authors: Marinella Ruospo; Valeria M Saglimbene; Suetonia C Palmer; Salvatore De Cosmo; Antonio Pacilli; Olga Lamacchia; Mauro Cignarelli; Paola Fioretto; Mariacristina Vecchio; Jonathan C Craig; Giovanni Fm Strippoli Journal: Cochrane Database Syst Rev Date: 2017-06-08
Authors: M Park; R Katz; M G Shlipak; D Weiner; R Tracy; V Jotwani; J Hughes-Austin; F Gabbai; C Y Hsu; M Pfeffer; N Bansal; A Bostom; O Gutierrez; M Sarnak; A Levey; J H Ix Journal: Am J Transplant Date: 2017-04-26 Impact factor: 8.086
Authors: William R Zhang; Timothy E Craven; Rakesh Malhotra; Alfred K Cheung; Michel Chonchol; Paul Drawz; Mark J Sarnak; Chirag R Parikh; Michael G Shlipak; Joachim H Ix Journal: Ann Intern Med Date: 2018-10-23 Impact factor: 25.391
Authors: Girish N Nadkarni; Kinsuk Chauhan; Veena Rao; Joachim H Ix; Michael G Shlipak; Chirag R Parikh; Steven G Coca Journal: Am J Kidney Dis Date: 2018-10-02 Impact factor: 8.860